Profile data is unavailable for this security.
About the company
AstraZeneca PLC is a science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Its pipeline forms a robust portfolio of investigational therapies in various stages of clinical development. Its pipeline includes the Alexion Rare Disease portfolio and comprises approximately 179 projects. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its BioPharmaceuticals products include Farxiga, Lokelma, Crestor, Breztri and others. Its geographical segments include United Kingdom, Rest of Europe, The Americas and Asia, Africa & Australasia. It is also focused on discovering, developing, and manufacturing of T-cell receptor therapies.
- Revenue in GBP (TTM)36.02bn
- Net income in GBP2.67bn
- LocationAstraZeneca PLC1 Francis Crick AvenueCAMBRIDGE CB2 0AAUnited KingdomGBR
- Phone+44 207 304 5000
- Fax+44 207 604 8151
Mergers & acquisitions
|Acquired company||Deal status||Date||Date /|
|AZN:LSE since |
|Neogene Therapeutics||Announced||30 Nov 2022||30 Nov 2022Announced||0.96%||--|
|Neogene Therapeutics Inc||Deal completed||29 Nov 2022||29 Nov 2022Deal completed||1.05%||320.00m|
|TeneoTwo Inc||Deal completed||05 Jul 2022||05 Jul 2022Deal completed||3.31%||1.27bn|